BioNTech SE: BioNTech Announces First Quarter Financial Results and Corporate Update

First quarter revenues of €6.4 billion1, net income of €3.7 billion and fully diluted earnings per share of €14.24 ($15.972)Reiterates BioNTech COVID-19 2022 vaccine revenue guidance of €13 billion to

Related Keywords

Turkey ,Germany ,United States ,Israel ,Federal Republic Of Germany ,Israeli ,American ,Matinas Biopharma ,Sylke Maas ,Jens Holstein ,Biontech Ribomab ,Ugur Sahin ,Fosun Pharma ,Genentech ,German Central Bank Deutsche Bundesbank ,Influenza Vaccine Program ,Vaccine Program ,Development Expenses ,Pfizer ,Crescendo Biologics Ltd ,Global External Communications ,European Commission ,Drug Administration ,American Association For Cancer Research ,Biontech Group ,Instadeep Ltd ,African Union ,Roche Group ,Israeli Ministry Of Health ,Year Expenses ,Year Tax Assumptions ,American Depositary Shares ,Management Board ,Supervisory Board ,Annual General Meeting ,Contract Manufacturing ,Administrative Expenses ,Cash Deposits ,Trade Receivables ,Annual Report ,Quarterly Report ,Current Report ,German Central Bank ,Deutsche Bundesbank ,Full Year ,Corporate Update ,Emergency Use Authorization ,Israeli Ministry ,American Association ,Cancer Research ,Federal Republic ,Lipid Nanocrystal ,Sustainability Report ,Investor Relations ,Virtual Capital Markets Day ,New Technologies ,Private Securities Litigation Reform Act ,Consolidated Statements ,Biontech ,Nnounces ,First ,Quarter ,Financial ,Results ,Corporate ,Update ,